Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank57
5Y CAGR-31.3%
Studio
Year-over-Year Change

Year-over-year operating income growth rate

5Y CAGR
-31.3%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
202548.02%
202463.36%
202326.18%
2022-3.03%
202191.26%
2020313.36%
20192.48%
2018-185.59%
2017197.35%
2016-203.11%